Cart (0 Items)
Your cart is currently empty.
View Products-
-
-
Itolizumab Biosimilar – Anti-CD6 mAb – Research Grade
| Size | 100ug, 1MG |
|---|---|
| Isotype | IgG1, kappa |
| Brand | ProteoGenix |
| Product type | Primary Antibodies |
| Clonality | Monoclonal Antibody |
| Expression system | Mammalian cells |
| Applications | Elisa, WB |
| Product name | Itolizumab Biosimilar - Anti-CD6 mAb - Research Grade |
|---|---|
| Source | CAS 1116433-11-4 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Aliases /Synonyms | Itolizumab,T1h,CD6,anti-CD6 |
| Reference | PX-TA1246 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
Description of Itolizumab Biosimilar - Anti-CD6 mAb - Research Grade
General information on Anti-CD6[Homo sapiens] (Itolizumab) Monoclonal Antibody
Itolizumab is investigated for the treatment of patients Hospitalized With COVID-19.
SDS-PAGE for Itolizumab Biosimilar - Anti-CD6 mAb
Itolizumab Biosimilar - Anti-CD6 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Related products
Antigen
CD63 Recombinant Protein
PX-P4087 329€
Antigen
Clostridium Cwp84 Recombinant Protein
PX-P1083 210€
Antigen
Human CD63 Recombinant Protein
PX-P3052 210€
Antigen
Human PDCD6IP Recombinant Protein
PX-P3047 210€
Antigen
Rainbow trout rtCD64s Recombinant Protein
PX-P3064 210€
Antigen
Human CD66b recombinant protein
PX-P5120 110€
Antigen
CD66a recombinant protein
PX-P5131 420€
Antigen
FCGR1 recombinant protein
PX-P5190 420€
ELISA
Itolizumab ELISA Kit
KPTX220 1179€Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.